Philips to nominate Feike Sijbesma and Peter Löscher as members of the Supervisory Board

Comunicato Stampa disponibile solo in lingua originale. 

Amsterdam, the Netherlands – Royal #philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it will propose the appointments of #feikesijbesma and #peterloscher as new members of the Supervisory Board to the Annual General Meeting of Shareholders (AGM), which will be held on April 30, 2020.

“We are pleased that #feikesijbesma and #peterloscher are available to join Philips’ Supervisory Board,” said Jeroen van der Veer, Chairman of the Supervisory Board of Royal #philips. “Mr. Sijbesma is a recognized business and sustainability leader, while Mr. Löscher is a seasoned business leader in the medical technology and pharmaceutical industries. Their outstanding experience will be highly valuable to #philips, as the company is expanding its leadership in health technology solutions, on a mission to make the world healthier and more sustainable through innovation.”

"Feike Sijbesma is a recognized business and sustainability leader, while #peterloscher is a seasoned business leader in the medical technology and pharmaceutical industries. Their outstanding experience will be highly valuable to #philips." Jeroen van der Veer, Chairman of the Supervisory Board of Royal #philips.

Subject to his appointment, Mr. Sijbesma will become Vice-Chairman alongside the current Vice-Chairwoman Christine Poon, whose third term will expire in 2021.

Additionally, #philips will propose the re-appointment of Ms. Neelam Dhawan (Indian, 1959) for a period of two years as member of the Supervisory Board in light of her in-depth knowledge of the IT industry, including software engineering, research and IT services. Subject to her re-appointment, Ms. Dhawan will retain her current position within the Audit Committee.

Mr. Sijbesma (Dutch, 1959) currently is CEO and Chairman of the Managing Board of Royal DSM. Under his leadership, DSM has gone through a significant transformation and repositioned itself from a chemical company into a life sciences & materials sciences company. After 20 years on the DSM Managing Board and almost 13 years as its CEO, Mr. Sijbesma recently decided to step down as DSM’s CEO and leave the company per May 1, 2020.

Mr. Löscher (Austrian, 1957) has held various executive leadership positions in the medical technology and pharmaceutical industries, including as President and CEO of Siemens AG, President of Global Human Health and Member of the Executive Board of Merck & Co., and CEO of GE Healthcare Bio-Sciences and member of GE’s #corporate Executive Council.